TrialOncotarget2015

Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.

Hyo Song Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.